HC Wainwright & Co. Reiterates Buy on Marinus Pharma, Maintains $27 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Douglas Tsao reiterates a Buy rating on Marinus Pharma (NASDAQ:MRNS) and maintains a $27 price target.
June 14, 2023 | 10:18 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Douglas Tsao reiterates a Buy rating on Marinus Pharma and maintains a $27 price target.
The reaffirmed Buy rating and maintained $27 price target by HC Wainwright & Co. analyst Douglas Tsao indicates a positive outlook for Marinus Pharma. This news is likely to have a positive short-term impact on the stock price as it shows confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100